Compare Agilent Technologies Inc (A) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilent Technologies Inc vs Summit Therapeutics Inc — how do they compare? Agilent Technologies Inc trades at $149.5 (market cap $42.22B), while Summit Therapeutics Inc trades at $15.6 (market cap $12.06B). The key difference: Agilent Technologies Inc is far larger — about 3.5× Summit Therapeutics Inc's market cap, and Agilent Technologies Inc pays a 0.68% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| A | SMMT | |
|---|---|---|
Market Cap | $42.22B | $12.06B |
Sector | Health | Health |
52-Week High | $157.20 | $26.98 |
52-Week Low | $110.24 | $12.55 |
Enterprise Value | $43.77B | $11.39B |
Dividend Yield | 0.68% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
